NCT03431688

Tailored Therapy for Clarithromycin-Resistant H. Pylori

Efficacy Comparison of Metronidazole-based Triple and Bismuth-based Quadruple Therapy for Clarithromycin Resistant-Helicobacter Pylori Infection: Randomized Controlled Trial

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 782 (actual)
• Sponsor: Kangdong Sacred Heart Hospital · Academic / Other
• Sex: All
• Age: 19 Years – 85 Years
• Healthy volunteers: Not accepted

Summary

Clarithromycin-resistant H. pylori is the main cause of H. pylori eradication failure. Tailored therapy on the basis of detection of a clarithromycin resistance mutation by PCR has been studied recently, however, there have been few studies comparing treatment regimen in patient with clarithromycin-resistant H. pylori. We used sequencing-based clarithromycin resistance mutation and aimed to compare PAM (proton pump inhibitor, amoxicilline, metronidazole) regimen and PBMT (proton pump inhibitor, bismuth, metronidazole, tetracyclin) regimen in patient with clarithromycin-resistant H. pylori.

Conditions

• Helicobacter Pylori Infection

Interventions

Type	Name	Description
DRUG	PAM	treatment with PPI, metonidazole, amoxicillin
DRUG	PBMT	treatment with PPI, metonidazole, bismuth, tetracyclin

Timeline

• Start date: 2018-10-01
• Primary completion: 2020-10-30
• Completion: 2020-12-30
• First posted: 2018-02-13
• Last updated: 2025-09-22

Locations

1 site across 1 country: South Korea